Organizational Update

Stroke

Volumn 46, Issue 5, 2015, Pages e123-

  Mendis, Shanthi ^a   Davis, Stephen ^b   Norrving, Bo ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LUND UNIVERSITY   (Sweden)

Author keywords

global assessment; risk factor; stroke delivery; stroke prevention

Indexed keywords

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETES MELLITUS; FOLLOW UP; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; HYPERTENSION; LETTER; NON COMMUNICABLE DISEASE; OBESITY; PHYSICAL INACTIVITY; PREMATURE MORTALITY; PREVENTION AND CONTROL; PRIORITY JOURNAL; SUSTAINABLE DEVELOPMENT; UNITED NATIONS; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION; HEALTH SERVICE; STROKE; VASCULAR DISEASES;

HEALTH SERVICES NEEDS AND DEMAND; HUMANS; STROKE; VASCULAR DISEASES; WORLD HEALTH ORGANIZATION;

EID: 84937217413     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.008097     Document Type: Letter

References (5)

1. Tuñón J, Cristóbal C, Tarín N, Aceña Á, González-Casaus ML, Huelmos A, et al. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One. 2014;9:e95402. doi: 10.1371/journal.pone.0095402.
2. Panwar B, Jenny NS, Howard VJ, Wadley VG, Muntner P, Kissela BM, et al. Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke. 2015;46:322-328. doi: 10.1161/STROKEAHA.114.007489.
3. di Giuseppe R, Kuhn T, Hirche F, Buijsse B, Dierkes J, Fritsche A, et al. Plasma fibroblast growth factor 23 and risk of cardiovascular disease: Results from the epic-Germany case-cohort study [published online ahead of print December 21, 2014]. Eur J Epidemiol. http://link.springer.com/article/10.1007/s10654-014-9982-4/fulltext.html. Accessed December 21, 2014.
4. Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, et al. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology. 2014;82:1700-1706. doi: 10.1212/WNL.0000000000000410.
5. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail. 2014;7:409-417. doi: 10.1161/CIRCHEARTFAILURE.113.000952.